OLMA experienced a severe 65% cash burn dropping from $139.5M to $48.3M while operating losses widened significantly to -$162.5M, creating potential liquidity concerns for this clinical-stage biotech.
The dramatic cash decline combined with worsening operating cash flow (-$146.7M vs -$104.4M) suggests OLMA may face funding pressures within the next 12-18 months if burn rates continue. The company appears to have raised capital (evidenced by the share count increase from 68.3M to 87.2M shares plus pre-funded warrants), but the proceeds were insufficient to offset the accelerated cash consumption from expanded R&D activities.
OLMA's financial position deteriorated significantly with cash dropping 65% to $48.3M while R&D expenses surged 27% to $157.7M, driving operating losses 26% higher to -$178.7M. Despite raising capital (share count increased ~28% including warrants), the company burned through approximately $91M in cash while liabilities increased 31% to $54.9M. The overall picture signals mounting financial pressure for this clinical-stage company, with accelerating losses and a rapidly depleting cash runway that may necessitate additional financing in the near term.
Cash declined 65.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Capex reduced 56.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Operating cash flow fell 40.6% — earnings quality concerns; investigate working capital changes and non-cash items.
Liabilities grew 30.6% — significant increase in debt or obligations, assess impact on financial flexibility.
R&D investment increased 26.6% — signals commitment to future product development, though near-term margin impact.
Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.
Net income declined 25.5% — review whether driven by operations, interest costs, or non-recurring items.
Current liabilities rose 24.1% — increased short-term obligations, watch current ratio.
Asset base grew 18.3% — expansion through organic growth, acquisitions, or capital deployment.
Current assets grew 17.6% — improving short-term liquidity or inventory/receivables build.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →